---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-200597"
form_type: "8-K"
ticker: "XAGE"
cik: "0001842939"
company_name: "Longevity Health Holdings, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T19:03:35.306261+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Carmell Corp to acquire Axolotl Biologix for up to $140M; Axolotl TTM rev $50M, EBITDA $5M

## Summary
- Axolotl had unaudited TTM revenue ~$50M and TTM EBITDA ~$5M as of June 30, 2023.
- Initial consideration: $8M cash + $57M in CTCX stock ($65M total), plus up to $75M in milestone payments.
- Axolotl's human amnion allografts are FDA-compliant; two products added to CMS Part B pricing in Q2 2023.
- Transaction expected to close in Q3 2023; Axolotl shareholders subject to 12-month lock-up.
- Company changes name to Carmell Corporation; Axolotl CEO Josh Sandberg becomes Strategic Advisor.

## SEC filing metadata
- accession: 0001193125-23-200597
- form_type: 8-K
- ticker: XAGE
- cik: 0001842939
- company_name: Longevity Health Holdings, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/0001193125-23-200597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/d525835d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-200597
- JSON: https://secwatch.observer/filing/0001193125-23-200597.json
- Plain text: https://secwatch.observer/filing/0001193125-23-200597.txt

## Key facts
- Governance Changes
  Longevity Health Holdings, Inc.: Company renamed from Carmell Therapeutics Corporation to Carmell Corporation (effective 2023-08-01).
  - Change: charter amendment
  - Effective: 2023-08-01
  source text: On August 1, 2023, the board of directors of the Company approved and adopted an amendment (the “ Charter Amendment ”) to the Company’s existing amended and restated certificate of incorporation to change the name of the Company from “Carmell Therapeutics Corporation” to “Carmell Corporation.”
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/0001193125-23-200597-index.htm
- Material Agreements
  Longevity Health Holdings, Inc. entered into Agreement and Plan of Merger with Axolotl Biologix, Inc. valued at up to approximately $8.0 million in cash, a number of shares of the Company’s common stock equal to (effective 2023-07-26).
  - Action: entry
  - Agreement: merger
  - Counterparty: Axolotl Biologix, Inc.
  - Value: up to approximately $8.0 million in cash, a number of shares of the Company’s common stock equal to
  - Effective: 2023-07-26
  source text: On July 26, 2023, Carmell Corporation (formerly Carmell Therapeutics Corporation) (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Aztec Merger Sub, Inc. (“ Merger Sub ”) and Axolotl Biologix, Inc. (“ Axolotl ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842939/000119312523200597/0001193125-23-200597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.